ReviewBiochimica et biophysica acta2014
Genetic variation: effect on prostate cancer.
Review in Biochimica et biophysica acta, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancer.Aging · 2018Pooled it
- Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.Scientific reports · 2017Pooled it
- Trial
- Assessing the effectiveness of MRI,Polish journal of radiology · 2024Article
- Review
- Xenoestrogen interference with nongenomic signaling actions of physiological estrogens in endocrine cancer cells.Steroids · 2019Article
- Humanity in a Dish: Population Genetics with iPSCs.Trends in cell biology · 2018Review
- Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?Pathology oncology research : POR · 2017Article
- Genetic Association betweenFrontiers in physiology · 2017Article
- Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.Pharmacogenomics · 2016Article
- Article
- Could androgens be relevant to partly explain why men have lower life expectancy than women?Journal of epidemiology and community health · 2016Article
- Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.Hormones & cancer · 2016Review
- Surgery and hormonal treatment for prostate cancer and sexual function.Translational andrology and urology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The crucial role of androgens in the development of prostate cancer is well established. The aim of this review is to examine the role of constitutional (germline) and tumor-specific (somatic) polymorphisms within important regulatory genes of prostate cancer. These include genes encoding enzymes of the androgen biosynthetic pathway, the androgen receptor gene, genes that encode proteins of the signal transduction pathways that may have a role in disease progression and survival, and genes involved in prostate cancer angiogenesis. Characterization of deregulated pathways critical to cancer cell growth have lead to the development of new treatments, including the CYP17 inhibitor abiraterone and clinical trials using novel drugs that are ongoing or recently completed [1]. The pharmacogenetics of the drugs used to treat prostate cancer will also be addressed. This review will define how germline polymorphisms are known affect a multitude of pathways, and therefore phenotypes, in prostate cancer etiology, progression, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.